Every 10-Q that Cvrx, Inc. (CVRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CVRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVRX filings page.
CVRx, Inc. reported first-quarter 2026 revenue of $14.8 million, up 20% from $12.3 million a year earlier, driven mainly by U.S. heart failure sales. U.S. revenue rose to $13.7 million as implanting centers and sales territories expanded, while European revenue was roughly flat.
Gross margin improved to 87% from 84% as manufacturing efficiencies lowered cost per unit. Operating expenses increased modestly, and the company recorded a net loss of $13.1 million, slightly better than the prior-year loss. Cash and cash equivalents were $72.3 million, and term loan borrowings rose to $60.0 million after a January 2026 amendment expanded the facility to $100.0 million and extended maturity to 2031. Management expects continued operating losses as it invests in commercialization of its Barostim neuromodulation device.
CVRx, Inc. reported third‑quarter results showing steady top‑line growth and improved margins while remaining unprofitable. Revenue for the three months ended September 30, 2025 was $14.7 million, up 10% year over year, driven mainly by U.S. heart failure implants. Gross margin rose to 87% from 83% on higher average selling prices and manufacturing efficiencies.
Operating expenses were $25.0 million, yielding a loss from operations of $12.3 million. Net loss was $12.9 million (basic and diluted net loss per share $0.49). For the nine months, revenue reached $40.6 million (up 13%) with a net loss of $41.4 million.
Cash and cash equivalents were $85.1 million as of September 30, 2025, with $50.0 million of long‑term debt outstanding under the Innovatus loan. The company issued 543,462 shares via its ATM for gross proceeds of $9.5 million during the nine‑month period. CMS finalized the 2026 Medicare Physician Fee Schedule adding Category I CPT codes for Barostim, effective January 1, 2026.